A systematic review of Bannayan - Riley - Ruvalcaba syndrome.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
received:
07
10
2023
accepted:
02
09
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
10
9
2024
Statut:
epublish
Résumé
Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a rare overgrowth condition caused by a pathogenic variant in the phosphatase and tensin homolog (PTEN) gene and belongs to a group of disorders called PTEN hamartoma tumor syndrome (PHTS). The diagnosis is often complicated by great phenotypic diversity. Furthermore, to this date treatment options are limited. Here we performed a systematic review using PubMed, Cochrane, and Scopus databases to identify cases of pediatric patients diagnosed with BRRS and summarized information about the clinical presentation, treatment, and long-term patient care. A total of 83 pediatric patients with BRRS were identified. The most common clinical findings were macrocephaly (77%) and developmental disorders (63%). Surgical interventions were the treatment of choice, described in 19 articles. Patient surveillance was proposed in 15 case reports and mostly aimed at periodic cancer screening. Recognition of BRRS clinical symptoms and early referral to a geneticist is important for better disease control and overall prognosis. As targeted treatment is still lacking, symptom relief and long-term surveillance remain the main management strategies.
Identifiants
pubmed: 39256443
doi: 10.1038/s41598-024-71991-2
pii: 10.1038/s41598-024-71991-2
doi:
Substances chimiques
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21119Informations de copyright
© 2024. The Author(s).
Références
Pulido, R. PTEN: A yin-yang master regulator protein in health and disease. Methods San Diego Calif. 77–78, 3–10 (2015).
pubmed: 25843297
doi: 10.1016/j.ymeth.2015.02.009
Yehia, L., Keel, E. & Eng, C. The clinical spectrum of PTEN mutations. Annu. Rev. Med. 27(71), 103–116 (2020).
doi: 10.1146/annurev-med-052218-125823
Macken, W. L., Tischkowitz, M. & Lachlan, K. L. PTEN hamartoma tumor syndrome in childhood: A review of the clinical literature. Am. J. Med. Genet. C Semin. Med. Genet. 181(4), 591–610 (2019).
pubmed: 31609537
doi: 10.1002/ajmg.c.31743
Gorlin, R. J., Cohen, M. M., Condon, L. M. & Burke, B. A. Bannayan-Riley-Ruvalcaba syndrome. Am. J. Med. Genet. 44(3), 307–314 (1992).
pubmed: 1336932
doi: 10.1002/ajmg.1320440309
Mester, J. & Eng, C. Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet. Med. 14(9), 819–822 (2012).
pubmed: 22595938
pmcid: 3651836
doi: 10.1038/gim.2012.51
Tan, M. H. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res. 18(2), 400–407 (2012).
pubmed: 22252256
pmcid: 3261579
doi: 10.1158/1078-0432.CCR-11-2283
Hammill, A. M. et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr. Blood Cancer 57(6), 1018–1024 (2011).
pubmed: 21445948
doi: 10.1002/pbc.23124
Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 29(372), n71 (2021).
doi: 10.1136/bmj.n71
Moola S MPF. Chapter 7: Systematic reviews of etiology and risk. In: JBI Manual for Evidence Synthesis [Internet]. JBI; 2020 [cited 2024 Jun 26]. Available from: https://jbi-global-wiki.refined.site/space/MANUAL/355863557/Previous+versions?attachment=/download/attachments/355863557/JBI_Reviewers_Manual_2020June.pdf&type=application/pdf&filename=JBI_Reviewers_Manual_2020June.pdf#page=217
Munn, Z. et al. Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. JBI Database Syst. Rev. Implement Rep. https://doi.org/10.11124/JBISRIR-D-19-00099 (2019).
doi: 10.11124/JBISRIR-D-19-00099
Ahmed, S. F. et al. Balanced translocation of 10q and 13q, including the PTENGene, in a boy with a human chorionic gonadotropin-secreting tumor and the Bannayan-riley-Ruvalcaba syndrome. J. Clin. Endocrinol. Metab. 84(12), 4665–4670 (1999).
doi: 10.1210/jcem.84.12.6178
Arch, E. M. et al. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with cowden disease. Am. J. Med. Genet. 71(4), 489–493 (1997).
pubmed: 9286463
doi: 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B
Bhargava, R. Bannayan-Riley-Ruvalcaba syndrome: MRI neuroimaging features in a series of 7 patients. Am. J. Neuroradiol. 35, 402 (2014).
pubmed: 23907246
pmcid: 7965774
doi: 10.3174/ajnr.A3680
Bishop, P. R., Nowicki, M. J. & Parker, P. H. What syndrome is this? Ruvalcaba-Myhre-Smith syndrome. Pediatr. Dermatol. 17(4), 319–321 (2000).
pubmed: 10990586
doi: 10.1046/j.1525-1470.2000.01787.x
Blum, R. R., Rahimizadeh, A., Kardon, N., Lebwohl, M. & Wei, H. Genital Lentigines in a 6-year-old boy with a family history of cowden’s disease: Clinical and genetic evidence of the linkage between Bannayan–Riley–Ruvacalba syndrome and Cowden’s disease. J. Cutan Med. Surg. 5(3), 228–230 (2001).
pubmed: 11685670
Buisson, P. et al. Cutaneous lipoma in children: 5 cases with Bannayan-Riley-Ruvalcaba syndrome. J. Pediatr. Surg. 41(9), 1601–1603 (2006).
pubmed: 16952599
doi: 10.1016/j.jpedsurg.2006.05.013
Celebi, J. T. et al. Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN. J. Med. Genet. 36(5), 360–364 (1999).
pubmed: 10353779
pmcid: 1734369
Erkek, E. et al. Clinical and histopathological findings in Bannayan-Riley-Ruvalcaba syndrome. J. Am. Acad. Dermatol. 53(4), 639–643 (2005).
pubmed: 16198785
doi: 10.1016/j.jaad.2005.06.022
Ghusayni, R., Sachdev, M., Gallentine, W., Mikati, M. A. & McDonald, M. T. Hemimegalencephaly with Bannayan-Riley-Ruvalcaba syndrome. Epileptic Disord. 20(1), 30–34 (2018).
pubmed: 29444762
doi: 10.1684/epd.2018.0954
Golas, M. M. et al. Looking for the hidden mutation: Bannayan–Riley–Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A. Am. J. Med. Genet. A 179(7), 1383–1389 (2019).
pubmed: 31062505
doi: 10.1002/ajmg.a.61166
Gontijo, G. M. A. et al. Bannayan-Riley-Ruvalcaba syndrome with deforming lipomatous hamartomas in infant—Case report. An. Bras. Dermatol. 88(6), 982–985 (2013).
pubmed: 24474112
pmcid: 3900354
doi: 10.1590/abd1806-4841.20132730
Hansen-Kiss, E. et al. A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children. J. Med. Genet. 54(7), 471–478 (2017).
pubmed: 28526761
doi: 10.1136/jmedgenet-2016-104484
Hendriks, Y. M. C. et al. Bannayan-Riley-Ruvalcaba syndrome: Further delineation of the phenotype and management of PTEN mutation-positive cases. Fam. Cancer 2(2), 79–85 (2003).
pubmed: 14574156
doi: 10.1023/A:1025713815924
Hızarcıoğlu-Gülşen, H. et al. Polyposis deserves a perfect physical examination for final diagnosis: Bannayan-Riley-Ruvalcaba syndrome. Turk. J. Pediatr. 59(1), 80–83 (2017).
pubmed: 29168369
doi: 10.24953/turkjped.2017.01.014
Iacobas, I. et al. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr. Blood Cancer 57(2), 321–323 (2011).
pubmed: 21360661
doi: 10.1002/pbc.23098
Iskandarli, M., Yaman, B. & Aslan, A. A case of B annayan– R iley– R uvalcaba syndrome. A new clinical finding and brief review. Int. J. Dermatol. 55(9), 1040–1043 (2016).
pubmed: 26228616
doi: 10.1111/ijd.13013
Israel, J., Lessick, M., Szego, K. & Wong, P. Translocation 19;Y in a child with Bannayan-Zonana phenotype. J. Med. Genet. 28(6), 427–428 (1991).
pubmed: 1870104
pmcid: 1016916
doi: 10.1136/jmg.28.6.427
Kurek, K. C. et al. PTEN hamartoma of soft tissue: A distinctive lesion in PTEN syndromes. Am. J. Surg. Pathol. 36(5), 671–687 (2012).
pubmed: 22446940
pmcid: 3367317
doi: 10.1097/PAS.0b013e31824dd86c
Laguna, B. A., Iyer, R. S., Rudzinski, E. R., Roybal, J. L. & Stanescu, A. L. Torsion of a giant mesocolic lipoma in a child with Bannayan-Riley-Ruvalcaba syndrome. Pediatr. Radiol. 45(3), 449–452 (2015).
pubmed: 25008800
doi: 10.1007/s00247-014-3083-0
Longy, M. et al. Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. J. Med. Genet. 35(11), 886–889 (1998).
pubmed: 9832032
pmcid: 1051478
doi: 10.1136/jmg.35.11.886
Lowichik, A. et al. Bannayan-Riley-Ruvalcaba syndrome: Spectrum of intestinal pathology including juvenile polyps. Pediatr. Dev. Pathol. 3(2), 155–161 (2000).
pubmed: 10679034
doi: 10.1007/s100240050019
Lynch, N. E., Lynch, S. A., McMenamin, J. & Webb, D. Bannayan-Riley-Ruvalcaba syndrome: A cause of extreme macrocephaly and neurodevelopmental delay. Arch. Dis. Child. 94(7), 553–554 (2009).
pubmed: 19321504
doi: 10.1136/adc.2008.155663
Niklinska, E. B., Lyons, E. M., Hicks, A., Zwerner, J. P. & Albers, S. E. Bannayan-Riley-Ruvalcaba syndrome with gingival hyperpigmentation and facial papules. Pediatr. Dermatol. 38(5), 1351–1353 (2021).
pubmed: 34259361
doi: 10.1111/pde.14691
O’Rourke, D. J., Twomey, E., Lynch, S. A. & King, M. D. Cortical dysplasia associated with the PTEN mutation in Bannayan Riley Ruvalcaba syndrome: A rare finding. Clin. Dysmorphol. 21(2), 91–92 (2012).
pubmed: 22327138
doi: 10.1097/MCD.0b013e328351639d
Valentina, P. et al. Thyroid involvement in two patients with Bannayan-Riley-Ruvalcaba syndrome. J. Clin. Res. Pediatr. Endocrinol. 5(4), 261–265 (2013).
doi: 10.4274/Jcrpe.984
Piccione, M. et al. PTEN hamartoma tumor syndromes in childhood: Description of two cases and a proposal for follow-up protocol. Am. J. Med. Genet. A 161(11), 2902–2908 (2013).
doi: 10.1002/ajmg.a.36266
Prat, D., Ben Bassat Mizrachi, I. & Vishnevskia-Dai, V. Intermediate uveitis in a child with phosphatase and tensin homolog gene mutation and Bannayan-Riley-Ruvalcaba syndrome. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-224079 (2019).
doi: 10.1136/bcr-2017-224079
pubmed: 31603075
pmcid: 6381972
Schwab, J. G., Pena, L., Waggoner, D. & Pytel, P. Two children with macrocephaly, developmental delay, and PTEN mutation. Clin. Pediatr. (Phila) 48(1), 89–92 (2009).
pubmed: 18626099
doi: 10.1177/0009922808321679
Soysal, Y., Acun, T., Lourenço, C., Marques, W. & Yakıcıer, M. Muscle Hemangiomatosis presenting as a severe feature in a patient with the Pten mutation: Expanding the phenotype of vascular malformations in Bannayan-Riley-ruvalcaba syndrome. Balk. J. Med. Genet. 15(1), 45–50 (2012).
doi: 10.2478/v10034-012-0007-x
Srinivasa, R. N. & Burrows, P. E. Dural arteriovenous malformation in a child with Bannayan-Riley-Ruvalcaba syndrome. AJNR Am. J. Neuroradiol. 27(9), 1927–1929 (2006).
pubmed: 17032868
pmcid: 7977879
Vincenzi, G. et al. Case report—Multinodular goiter in a patient with CONGENITAL HYPOTHYRoidism and Bannayan-Riley-Ruvalcaba syndrome: The possible synergic role of TPO and PTEN mutation. Front. Endocrinol. 8(14), 1205785 (2023).
doi: 10.3389/fendo.2023.1205785
Wanner, M., Elebi, J. T. & Peacocke, M. Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome. J. Am. Acad. Dermatol. 44(2), 183–187 (2001).
pubmed: 11174374
doi: 10.1067/mjd.2001.110390
Zambrano, E. et al. Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated tumor syndromes. Endocr. Pathol. 15(1), 55–64 (2004).
pubmed: 15067177
doi: 10.1385/EP:15:1:55
Pilarski, R. et al. Cowden Syndrome and the PTEN hamartoma tumor syndrome: Systematic review and revised diagnostic criteria. JNCI J. Natl. Cancer Inst. 105(21), 1607–1616 (2013).
pubmed: 24136893
doi: 10.1093/jnci/djt277
Pilarski, R. PTEN hamartoma Tumor syndrome: A clinical overview. Cancers 11(6), 844 (2019).
pubmed: 31216739
pmcid: 6627214
doi: 10.3390/cancers11060844
Plamper, M., Gohlke, B. & Woelfle, J. PTEN hamartoma tumor syndrome in childhood and adolescence—a comprehensive review and presentation of the German pediatric guideline. Mol. Cell. Pediatr. 9(1), 3 (2022).
pubmed: 35187600
pmcid: 8859017
doi: 10.1186/s40348-022-00135-1
Stanich, P. P. Colonic manifestations of PTEN hamartoma tumor syndrome: Case series and systematic review. World J. Gastroenterol. 20(7), 1833 (2014).
pubmed: 24587660
pmcid: 3930981
doi: 10.3748/wjg.v20.i7.1833
D’Ermo, G. & Genuardi, M. Gastrointestinal manifestations in PTEN hamartoma tumor syndrome. Best Pract. Res. Clin. Gastroenterol. 58–59, 101792 (2022).
pubmed: 35988965
doi: 10.1016/j.bpg.2022.101792
Cummings, K., Watkins, A., Jones, C., Dias, R. & Welham, A. Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics. J Neurodev Disord. 14(1), 1 (2022).
pubmed: 34983360
pmcid: 8903687
doi: 10.1186/s11689-021-09406-w
Ngeow, J., Sesock, K. & Eng, C. Clinical implications for germline PTEN spectrum disorders. Endocrinol. Metab. Clin. North Am. 46(2), 503–517 (2017).
pubmed: 28476234
doi: 10.1016/j.ecl.2017.01.013
Hobert, J. A. & Eng, C. PTEN hamartoma tumor syndrome: An overview. Genet. Med. 11(10), 687–694 (2009).
pubmed: 19668082
doi: 10.1097/GIM.0b013e3181ac9aea
Blumenthal, G. M. & Dennis, P. A. PTEN hamartoma tumor syndromes. Eur. J. Hum. Genet. 16(11), 1289–1300 (2008).
pubmed: 18781191
doi: 10.1038/ejhg.2008.162
Tan, M. H. et al. A clinical scoring system for selection of patients for PTEN Mutation testing is proposed on the basis of a prospective study of 3042 probands. Am. J. Hum. Genet. 88(1), 42–56 (2011).
pubmed: 21194675
pmcid: 3014373
doi: 10.1016/j.ajhg.2010.11.013
Adams, D. M. & Ricci, K. W. Vascular anomalies. Hematol. Oncol. Clin. North Am. 33(3), 455–470 (2019).
pubmed: 31030813
doi: 10.1016/j.hoc.2019.01.011
Komiya, T. et al. A pilot study of Sirolimus in subjects with cowden syndrome or other syndromes characterized by germline mutations in PTEN. Oncologist 24(12), 1510-e1265 (2019).
pubmed: 31350329
pmcid: 6975943
doi: 10.1634/theoncologist.2019-0514
Geeurickx, M. & Labarque, V. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations. J. Vasc. Surg. Venous Lymphat. Disord. 9(5), 1321–1333 (2021).
pubmed: 33737259
doi: 10.1016/j.jvsv.2021.03.001
Badawy, M., Ma, Y., Baldrighi, C., Oestreich, K. & Jester, A. Efficacy of mTOR inhibitors (sirolimus) in isolated limb overgrowth: A systematic review. J. Hand Surg. Eur. 47(7), 698–704 (2022).
doi: 10.1177/17531934211073866
Seront, E., Van Damme, A., Boon, L. M. & Vikkula, M. Rapamycin and treatment of venous malformations. Curr. Opin. Hematol. 26(3), 185–192 (2019).
pubmed: 30855337
doi: 10.1097/MOH.0000000000000498
Tischkowitz, M. et al. Cancer surveillance guideline for individuals with pten hamartoma tumour syndrome. Eur. J. Hum. Genet. 28(10), 1387–1393 (2020).
pubmed: 32533092
pmcid: 7608293
doi: 10.1038/s41431-020-0651-7